Tonix Pharmaceuticals (TNXP) Q2 FY26 earnings call

Tonix Pharmaceuticals reported strong Q2 FY26 results, driven by significant sales growth and increasing patient access for its fibromyalgia treatment, Tonmaya. The company is also advancing its mid-stage pipeline, including a pivotal Phase 2 study for TNX-102SL in MDD and preparing for a Phase 2 study for TNX-4800 in Lyme disease prevention. Management expects continued fluctuations in gross-to-net for Tonmaya in the near term as coverage agreements materialize.